




RealRate

PHARMACEUTICAL 2019

Spero Therapeutics Inc.
Rank 120 of 371



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai

The relative strengths and weaknesses of Spero Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Spero Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 264% points. The greatest weakness of Spero Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 74% points.

The company's Economic Capital Ratio, given in the ranking table, is -59%, being 273% points above the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	124,219
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	12,318
Liabilities, Non-Current	0
Other Assets	1,894
Other Compr. Net Income	-28
Other Expenses	0
Other Liabilities	833
Other Net Income	1,144
Property and Equipment	2,893
Research and Development	33,885
Revenues	3,966
Selling, General and Administrative Expense	12,887

Output Variable	Value in 1000 USD
Assets	129,006
Liabilities	13,151
Expenses	46,772
Stockholders Equity	115,855
Net Income	-41,662
Comprehensive Net Income	-41,676
Economic Capital Ratio	-59%